Bolt Biotherapeutics Merges with Prana Therapies, Secures $120M to Fund Inflammatory Pipeline

Bolt Biotherapeutics merges with Prana Therapies in a $120 million deal to advance PRA-216 through Phase 2 trials in asthma, COPD, and atopic dermatitis.